Authors
Latest:
Nab-Paclitaxel as Neoadjuvant Therapy for Breast CancerYu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer.
Latest:
Levantinib in the Management of Differentiated Thyroid CancerTherapy that targets angiogenesis has been extensively investigated in differentiated thyroid cancer (DTC) and has demonstrated significant antitumor activity.
Latest:
Clinical Outcomes for the Treatment of Pembrolizumab in Patients With Advanced Gastric CancerYung-Jue Bang, MD, PhD, professor of medical oncology, College of Medicine, Seoul National University, president, Biomedical Research Institute, Seoul National University Hospital, discusses the clinical results for the treatment of pembrolizumab in patients with advanced gastric cancer.
Latest:
Molecular Testing Helps Diagnose Low-Risk Thyroid CancerYuri E. Nikiforov, MD, PhD, discusses improvements in diagnosis of thyroid cancer including the classification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
Latest:
The Impacts of Chemotherapy Versus Immunotherapy in MelanomaYvonne Saenger, MD, director, melanoma immunotherapy, Columbia University Medical Center, discusses the impacts of chemotherapy and immunotherapy in melanoma.
Latest:
Questions to Still be Answered in MyelofibrosisZeev Estrov, MD, professor of medicine, MD Anderson Cancer Center, discusses questions that still need to be answered in the myelofibrosis field.
Latest:
EGFR Exon 20–Positive NSCLC: Future Directions in CareBefore closing out her discussion on novel therapy for EGFR exon 20–positive NSCLC, Zofia Piotrowska, MD, shares her hopes for future developments in care.
Latest:
Epcoritamab Delivers Durable Responses in Anthracycline-Ineligible LBCLFixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.
Latest:
Recent Progress and Unmet Needs in NSCLCDr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.
Latest:
Shift to Value-Based Care Brings New Desires for EHR CapabilitiesA survey shows doctors are looking to upgrade their EHR systems to better support value-based care by collecting patient outcome data and integrating with AI.
Latest:
Cervical Cancer Awareness Month: Challenges of Reaching At-Risk PopulationsDennis Scribner, Jr, MD, discusses the challenges for reaching patients who are at the greatest risk of developing cervical cancer.
Latest:
When to Use Targeted Therapy for Iodine-Refractory Thyroid CancerKrzysztof J. Misiukiewicz, MD, discusses when targeted therapy may be used for patients with NTRK-positive thyroid cancer.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
Addressing the Treatment Needs of Aging Patients With CancerWilliam Dale, MD, PhD, discusses the unmet needs of older patients requiring cancer treatment.
Latest:
Briquilimab Combination is Safe in MDS/AML Undergoing AlloHCTLori Muffly, MD, discusses findings a sub-analysis of a phase 1 study investigating briquilimab with low-dose total body radiation and fludarabine.
Latest:
Active Research on Uproleselan in Acute Myeloid LeukemiaBrian A. Jonas, MD, discusses studies investigating the use of uproleselan for the treatment of patients with acute myeloid leukemia.
Latest:
Study Investigates Hydroxychloroquine and Itraconazole in Ovarian CancerAinhoa Madariaga, MD, discusses the data from the phase 1/2 HYDRA-01 trial looking at hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer.
Latest:
Future Treatment Approaches for HCCClosing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.
Latest:
Breakthrough for NF1? Mirdametinib Shows Significant Tumor Reduction in All AgesChristopher Moertel, MD, discusses mirdametinib's mechanism of action and the implications of the phase 2b ReNeu trial of the agent in NF1-associated plexiform neurofibroma.
Latest:
Management of Adverse Events Related to Pacritinib in MyelofibrosisAshwin Kishtagari, MD, discusses the adverse events of pacritinib for patients with primary myelofibrosis and low platelet counts.
Latest:
TiNivo-2 Study Shows Comparable Patient-Reported Outcomes in RCCKathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 study.
Latest:
Assessing Detection Modalities for Breast Cancer RecurrenceAli Duffens, MD, discusses the relative effectiveness of different detection modalities in identifying breast cancer recurrences.
Latest:
Novel Delivery Systems, Unique Pairings Explored With Oncolytic VirusesOncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.
Latest:
Real-World Outcomes of Lenvatinib in RAI-Refractory Differentiated Thyroid CancerFrancis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from other clinical trials.
Latest:
Portell on the Changing Landscape of Mantle Cell LymphomaCraig A. Portell, MD, discusses the current standard of care for patients with relapsed/refractory mantle cell lymphoma and how sequencing therapies changed the landscape of mantle cell lymphoma treatment.
Latest:
Referral for CAR T Should Always Be Considered in R/R Multiple MyelomaKenneth Shain, MD, PhD, discusses why he recommends most patients with relapsed/refractory multiple myeloma be referred for evaluation to receive chimeric antigen receptor T-cell therapy.
Latest:
Buttin Reviews Results From PAOLA-1 in Ovarian CancerBarbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.
